Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1. Issue 24 (15th December 2017)

• Record Type: Journal Article
• Authors: Ma, Tianfang; Zou, Fangxia; Pusch, Stefan; Yang, Lijun; Zhu, Qihua; Xu, Yungen; Gu, Yueqing; von Deimling, Andreas; Zha, Xiaoming
• Is Part Of: Bioorganic & medicinal chemistry. Volume 25:Issue 24(2017)
• Page Start: 6379
• Page End: 6387
• Publication Date: 2017-12-15
• Subjects: IDH Isocitrate dehydrogenase -- TCA the tricarboxylic acid -- a-KG a-Ketoglutaric acid -- D2HG D-2-Hydroxyglutaric acid -- mIDH1 Mutant IDH1 -- mIDH2 Mutant IDH2 -- R132H Arg132 mutation to His -- R132C Arg132 mutation to Cys -- R140Q Arg140 mutation to Gln -- WT wild type -- BBB Blood Brain Barrier; Mutant IDH1 -- Inhibitors -- D-2-HG -- Allosteric -- BBB; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; Biochemistry -- Periodicals; Chemistry, Clinical -- Periodicals; Chemistry, Organic -- Periodicals; Chimie bio-organique -- Périodiques; Chimie pharmaceutique -- Périodiques; 615.19
• DOI: 10.1016/j.bmc.2017.10.009
• Languages: English
• ISSNs: 0968-0896

Abstract

Graphical abstract: Highlights: Synthesis of novel selective mIDH1 inhibitors with 3-pyrazine-2-yl-oxazolidin-2-ones scaffold. 3g shows potent inhibition against IDH1-132H and IDH1-132C as well as high selectivity over IDH1-WT. 3g can penetrate the blood–brain barrier (BBB). 3g might be a lead compound deserved further structural optimization. Abstract: Isocitrate dehydrogenases (IDHs) catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG) generating carbon dioxide and NADPH/NADH. Evidence suggests that the specific mutations in IDH1 are critical to the growth and reproduction of some tumor cells such as gliomas and acute myeloid leukemia, emerging as an attractive antitumor target. In order to discovery potent new mutant IDH1 inhibitors, we designed, synthesized and evaluated a series of allosteric mIDH1 inhibitors harboring the scaffold of 3-pyrazine-2-yl-oxazolidin-2-ones. All tested compounds effectively suppress the D-2-hydroxyglutarate (D-2-HG) production in cells transfected with IDH1-R132H and IDH1-R132C mutations at 10 μM and 50 μM. Importantly, compound3g owns the similar inhibitory activity to the positive agentNI-1 and shows no significant toxicity at the two concentrations. The parallel artificial membrane permeation assay of the blood–brain barrier (PAMPA-BBB) identified3g with a good ability to penetrate the blood–brain barrier (BBB). These findings indicate that3g deserves further optimization as a lead compound for the treatment of patients with IDH1 mutated brain cancers.